Globavend is trading at $0.77, down 9.41%, in after-hours trading, with broader market weakness likely contributing to the October 22 decline. - No new company-specific announcement explaining the decline was identified; the latest company release found was an October 13 conference announcement. - The S&P 500 fell 1.24% and the Nasdaq Composite 2.58% as technology shares faced pressure. - Available evidence points to a market-related explanation, not a confirmed Globavend-specific catalyst.